Background The oncogenesis of ovarian cancer is poorly understood. The aim of this study was to identify mRNAs differentially expressed between moderately and poorly differentiated (MD/PD) serous ovarian carcinomas (SC), serous ovarian borderline tumours (SBOT) and superficial scrapings from normal ovaries (SNO), and to correlate these mRNAs with clinical parameters including survival. Methods Differences in mRNA expression between MD/PD SC, SBOT and SNO were analyzed by global gene expression profiling (n = 23), validated by RT-qPCR (n = 41) and correlated with clinical parameters. Results Thirty mRNAs differentially expressed between MD/PD SC, SBOT and SNO were selected from the global gene expression analyses, and 21 were verified (p<0.01) by RT-qPCR. Of these, 13 mRNAs were differentially expressed in MD/PD SC compared with SNO (p<0.01) and were correlated with clinical parameters. ZNF385B was downregulated (FC = ？130.5, p = 1.2×10？7) and correlated with overall survival (p = 0.03). VEGFA was upregulated (FC = 6.1, p = 6.0×10？6) and correlated with progression-free survival (p = 0.037). Increased levels of TPX2 and FOXM1 mRNAs (FC = 28.5, p = 2.7×10？10 and FC = 46.2, p = 5.6×10？4, respectively) correlated with normalization of CA125 (p = 0.03 and p = 0.044, respectively). Furthermore, we present a molecular pathway for MD/PD SC, including VEGFA, FOXM1, TPX2, BIRC5 and TOP2A, all significantly upregulated and directly interacting with TP53. Conclusions We have identified 21 mRNAs differentially expressed (p<0.01) between MD/PD SC, SBOT and SNO. Thirteen were differentially expressed in MD/PD SC, including ZNF385B and VEGFA correlating with survival, and FOXM1 and TPX2 with normalization of CA125. We also present a molecular pathway for MD/PD SC.
References
[1]
Cancer in Norway (2011) Cancer Registry of Norway. Cancer in Norway 2009 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo.
[2]
Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212–236 caac.20121 [pii];10.3322/caac.20121 [doi].
[3]
Kommoss S, Schmidt D, Kommoss F, Hedderich J, Harter P, et al. (2009) Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol). Virchows Arch 454: 249–256 10.1007/s00428-009-0725-y [doi].
[4]
Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, et al. (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23: 41–44 10.1097/01.pgp.0000101080.35393.16 [doi].
[5]
Singer G, Oldt R III, Cohen Y, Wang BG, Sidransky D, et al. (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95: 484–486.
[6]
Singer G, Stohr R, Cope L, Dehari R, Hartmann A, et al. (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29: 218–224 00000478-200502000-00009 [pii].
[7]
Shih I, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164: 1511–1518.
[8]
Vang R, Shih I, Kurman RJ (2009) Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16: 267–282 10.1097/PAP.0b013e3181b4fffa [doi];00125480-200909000-00001 [pii].
[9]
Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, et al. (2005) Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65: 10602–10612 65/22/10602 [pii];10.1158/0008-5472.CAN-05-2240 [doi].
[10]
Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, et al. (2005) Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24: 1053–1065 1208298 [pii];10.1038/sj.onc.1208298 [doi].
[11]
Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609–615 nature10166 [pii];10.1038/nature10166 [doi].
[12]
Chon HS, Lancaster JM (2011) Microarray-based gene expression studies in ovarian cancer. Cancer Control 18: 8–15.
[13]
Gomez-Raposo C, Mendiola M, Barriuso J, Hardisson D, Redondo A (2010) Molecular characterization of ovarian cancer by gene-expression profiling. Gynecol Oncol 118: 88–92 S0090-8258(10)00262-3 [pii];10.1016/j.ygyno.2010.03.012 [doi].
[14]
Chien J, Fan JB, Bell DA, April C, Klotzle B, et al. (2009) Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecol Oncol 114: 3–11 S0090-8258(09)00211-X [pii];10.1016/j.ygyno.2009.04.002 [doi].
[15]
Anglesio MS, Arnold JM, George J, Tinker AV, Tothill R, et al. (2008) Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 6: 1678–1690 6/11/1678 [pii];10.1158/1541-7786.MCR-08-0193 [doi].
[16]
Zorn KK, Jazaeri AA, Awtrey CS, Gardner GJ, Mok SC, et al. (2003) Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res 9: 4811–4818.
[17]
Elgaaen BV, Haug KB, Wang J, Olstad OK, Fortunati D, et al. (2010) POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas. PLoS One 5: e13837 10.1371/journal.pone.0013837 [doi].
[18]
Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207–210.
[19]
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408 10.1006/meth.2001.1262 [doi];S1046-2023(01)91262-9 [pii].
[20]
O'Geen H, Squazzo SL, Iyengar S, Blahnik K, Rinn JL, et al. (2007) Genome-wide analysis of KAP1 binding suggests autoregulation of KRAB-ZNFs. PLoS Genet 3: e89 07-PLGE-RA-0115R2 [pii];10.1371/journal.pgen.0030089 [doi].
[21]
Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579–591 nrc2403 [pii];10.1038/nrc2403 [doi].
[22]
Ishigami SI, Arii S, Furutani M, Niwano M, Harada T, et al. (1998) Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 78: 1379–1384.
[23]
Siddiqui GK, Elmasry K, Wong Te Fong AC, Perrett C, Morris R, et al. (2010) Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer. Eur J Gynaecol Oncol 31: 156–159.
[24]
Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, et al. (2004) Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10: 3291–3300 10.1158/1078-0432.CCR-03-0409 [doi];10/10/3291 [pii].
[25]
Hata K, Watanabe Y, Nakai H, Hata T, Hoshiai H (2011) Expression of the vascular endothelial growth factor (VEGF) gene in epithelial ovarian cancer: an approach to anti-VEGF therapy. Anticancer Res 31: 731–737 31/2/731 [pii].
[26]
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, et al. (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: 2473–2483 10.1056/NEJMoa1104390 [doi].
[27]
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, et al. (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365: 2484–2496 10.1056/NEJMoa1103799 [doi].
[28]
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, et al. (2012) AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 30: suppl; abstr LBA5002 Available: http://www.asco.org/ASCOv2/Meetings/Abst？racts?&vmview=abst_detail_view&confID=11？4&abstractID=94636. Accessed 22 June 2012. Abdelwahed A, Bouhlel I, Skandrani I, Valenti K, Kadri M et al. (2007) Study of antimutagenic and antioxidant activities of gallic acid and 1,2,3,4,6-pentagalloylglucose from Pistacia lentiscus. Confirmation by microarray expression profiling. Chem Biol Interact 165: 1–13. S0009-2797(06)00289-4 [pii];10.1016/j.cbi.2006.10.003 [doi].
[29]
Gruss OJ, Vernos I (2004) The mechanism of spindle assembly: functions of Ran and its target TPX2. J Cell Biol 166: 949–955 10.1083/jcb.200312112 [doi];jcb.200312112 [pii].
[30]
Ramakrishna M, Williams LH, Boyle SE, Bearfoot JL, Sridhar A, et al. (2010) Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. PLoS One 5: e9983 10.1371/journal.pone.0009983 [doi].
[31]
Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, et al. (2010) Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res 16: 2518–2528 1078-0432.CCR-09-2214 [pii];10.1158/1078-0432.CCR-09-2214 [doi].
[32]
Shigeishi H, Ohta K, Hiraoka M, Fujimoto S, Minami M, et al. (2009) Expression of TPX2 in salivary gland carcinomas. Oncol Rep 21: 341–344.
[33]
Asteriti IA, Rensen WM, Lindon C, Lavia P, Guarguaglini G (2010) The Aurora-A/TPX2 complex: a novel oncogenic holoenzyme? Biochim Biophys Acta 1806: 230–239 S0304-419X(10)00058-2 [pii];10.1016/j.bbcan.2010.08.001 [doi].
[34]
Bayliss R, Sardon T, Vernos I, Conti E (2003) Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell 12: 851–862 S1097276503003927 [pii].
[35]
Pilarsky C, Wenzig M, Specht T, Saeger HD, Grutzmann R (2004) Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 6: 744–750 10.1593/neo.04277 [doi].
[36]
Li Q, Zhang N, Jia Z, Le X, Dai B, et al. (2009) Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res 69: 3501–3509 0008-5472.CAN-08-3045 [pii];10.1158/0008-5472.CAN-08-3045 [doi].
[37]
Raychaudhuri P, Park HJ (2011) FoxM1: a master regulator of tumor metastasis. Cancer Res 71: 4329–4333 0008-5472.CAN-11-0640 [pii];10.1158/0008-5472.CAN-11-0640 [doi].
[38]
Wang IC, Chen YJ, Hughes D, Petrovic V, Major ML, et al. (2005) Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 25: 10875–10894 25/24/10875 [pii];10.1128/MCB.25.24.10875-10894.2005 [doi].
[39]
Barsotti AM, Prives C (2009) Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene 28: 4295–4305 onc2009282 [pii];10.1038/onc.2009.282 [doi].
[40]
Emmanuel C, Gava N, Kennedy C, Balleine RL, Sharma R, et al. (2011) Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. PLoS One 6: e17617 10.1371/journal.pone.0017617 [doi].
[41]
Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61–70 nrc2293 [pii];10.1038/nrc2293 [doi].
[42]
Li F (2003) Survivin study: what is the next wave? J Cell Physiol 197: 8–29 10.1002/jcp.10327 [doi].
[43]
Ryan BM, O'Donovan N, Duffy MJ (2009) Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 35: 553–562 S0305-7372(09)00085-1 [pii];10.1016/j.ctrv.2009.05.003 [doi].
[44]
Kleinberg L, Florenes VA, Silins I, Haug K, Trope CG, et al. (2007) Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer 109: 228–238 10.1002/cncr.22426 [doi].
[45]
Qian X, Xi X, Li L (2011) Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma. Appl Immunohistochem Mol Morphol 19: 126–132 10.1097/PAI.0b013e3181e30dcd [doi].
